Molecular targets in malignant pleural mesothelioma treatment

Giulia Pasello, Adolfo Favaretto

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Malignant mesothelioma is an aggressive tumour of the serosal surfaces with poor prognosis and increasing incidence due to widespread previous asbestos exposure. Relative chemotherapeutic and radiotherapeutic resistance makes malignant pleural mesothelioma (MPM) difficult to manage, even though encouraging results were achieved with multimodality treatment. Better knowledge of angiogenesis and molecular pathways involved in MPM seems to be the right way to define new targets for systemic treatment. Neoangiogenesis may be considered as a critical step in the development of mesothelioma. Vascular endothelial growth factor (VEGF) and platelet derived growth factor (PDGF) are autocrine growth factors in MPM and epidermal growth factor receptor (EGFR) appears highly expressed in this tumour. Tyrosine kinase inhibitors (TKIs) targeting growth factors like vandetanib, dasatinib, and angiogenesis inhibitors like bevacizumab, are among the most promising agents under evaluation in clinical trials. Mesothelioma is a malignancy which owes its chemoresistance to an apoptotic defect. Thus the introduction of new biologic drugs like vorinostat, bortezomib, everolimus and temsirolimus, in the treatment of MPM finds a strong rationale. This review focuses on the current target therapies and evaluates future biologic approaches for the systemic management of MPM.

Original languageEnglish
Pages (from-to)1235-1244
Number of pages10
JournalCurrent Drug Targets
Volume10
Issue number12
DOIs
Publication statusPublished - 2009

Fingerprint

Tumors
Intercellular Signaling Peptides and Proteins
Angiogenesis Inhibitors
Asbestos
Platelet-Derived Growth Factor
Epidermal Growth Factor Receptor
Protein-Tyrosine Kinases
Vascular Endothelial Growth Factor A
Mesothelioma
Defects
Pharmaceutical Preparations
Neoplasms
Malignant Mesothelioma
Clinical Trials
Incidence
temsirolimus
Dasatinib
Everolimus
Bortezomib
vorinostat

Keywords

  • Angiogenesis
  • Apoptosis
  • Growth factor
  • Mesothelioma
  • Targeted therapies

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Clinical Biochemistry
  • Molecular Medicine

Cite this

Molecular targets in malignant pleural mesothelioma treatment. / Pasello, Giulia; Favaretto, Adolfo.

In: Current Drug Targets, Vol. 10, No. 12, 2009, p. 1235-1244.

Research output: Contribution to journalArticle

Pasello, Giulia ; Favaretto, Adolfo. / Molecular targets in malignant pleural mesothelioma treatment. In: Current Drug Targets. 2009 ; Vol. 10, No. 12. pp. 1235-1244.
@article{dad7ecb7b94d44b18e0a6bb57079bce3,
title = "Molecular targets in malignant pleural mesothelioma treatment",
abstract = "Malignant mesothelioma is an aggressive tumour of the serosal surfaces with poor prognosis and increasing incidence due to widespread previous asbestos exposure. Relative chemotherapeutic and radiotherapeutic resistance makes malignant pleural mesothelioma (MPM) difficult to manage, even though encouraging results were achieved with multimodality treatment. Better knowledge of angiogenesis and molecular pathways involved in MPM seems to be the right way to define new targets for systemic treatment. Neoangiogenesis may be considered as a critical step in the development of mesothelioma. Vascular endothelial growth factor (VEGF) and platelet derived growth factor (PDGF) are autocrine growth factors in MPM and epidermal growth factor receptor (EGFR) appears highly expressed in this tumour. Tyrosine kinase inhibitors (TKIs) targeting growth factors like vandetanib, dasatinib, and angiogenesis inhibitors like bevacizumab, are among the most promising agents under evaluation in clinical trials. Mesothelioma is a malignancy which owes its chemoresistance to an apoptotic defect. Thus the introduction of new biologic drugs like vorinostat, bortezomib, everolimus and temsirolimus, in the treatment of MPM finds a strong rationale. This review focuses on the current target therapies and evaluates future biologic approaches for the systemic management of MPM.",
keywords = "Angiogenesis, Apoptosis, Growth factor, Mesothelioma, Targeted therapies",
author = "Giulia Pasello and Adolfo Favaretto",
year = "2009",
doi = "10.2174/138945009789753200",
language = "English",
volume = "10",
pages = "1235--1244",
journal = "Current Drug Targets",
issn = "1389-4501",
publisher = "Bentham Science Publishers B.V.",
number = "12",

}

TY - JOUR

T1 - Molecular targets in malignant pleural mesothelioma treatment

AU - Pasello, Giulia

AU - Favaretto, Adolfo

PY - 2009

Y1 - 2009

N2 - Malignant mesothelioma is an aggressive tumour of the serosal surfaces with poor prognosis and increasing incidence due to widespread previous asbestos exposure. Relative chemotherapeutic and radiotherapeutic resistance makes malignant pleural mesothelioma (MPM) difficult to manage, even though encouraging results were achieved with multimodality treatment. Better knowledge of angiogenesis and molecular pathways involved in MPM seems to be the right way to define new targets for systemic treatment. Neoangiogenesis may be considered as a critical step in the development of mesothelioma. Vascular endothelial growth factor (VEGF) and platelet derived growth factor (PDGF) are autocrine growth factors in MPM and epidermal growth factor receptor (EGFR) appears highly expressed in this tumour. Tyrosine kinase inhibitors (TKIs) targeting growth factors like vandetanib, dasatinib, and angiogenesis inhibitors like bevacizumab, are among the most promising agents under evaluation in clinical trials. Mesothelioma is a malignancy which owes its chemoresistance to an apoptotic defect. Thus the introduction of new biologic drugs like vorinostat, bortezomib, everolimus and temsirolimus, in the treatment of MPM finds a strong rationale. This review focuses on the current target therapies and evaluates future biologic approaches for the systemic management of MPM.

AB - Malignant mesothelioma is an aggressive tumour of the serosal surfaces with poor prognosis and increasing incidence due to widespread previous asbestos exposure. Relative chemotherapeutic and radiotherapeutic resistance makes malignant pleural mesothelioma (MPM) difficult to manage, even though encouraging results were achieved with multimodality treatment. Better knowledge of angiogenesis and molecular pathways involved in MPM seems to be the right way to define new targets for systemic treatment. Neoangiogenesis may be considered as a critical step in the development of mesothelioma. Vascular endothelial growth factor (VEGF) and platelet derived growth factor (PDGF) are autocrine growth factors in MPM and epidermal growth factor receptor (EGFR) appears highly expressed in this tumour. Tyrosine kinase inhibitors (TKIs) targeting growth factors like vandetanib, dasatinib, and angiogenesis inhibitors like bevacizumab, are among the most promising agents under evaluation in clinical trials. Mesothelioma is a malignancy which owes its chemoresistance to an apoptotic defect. Thus the introduction of new biologic drugs like vorinostat, bortezomib, everolimus and temsirolimus, in the treatment of MPM finds a strong rationale. This review focuses on the current target therapies and evaluates future biologic approaches for the systemic management of MPM.

KW - Angiogenesis

KW - Apoptosis

KW - Growth factor

KW - Mesothelioma

KW - Targeted therapies

UR - http://www.scopus.com/inward/record.url?scp=72849130471&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=72849130471&partnerID=8YFLogxK

U2 - 10.2174/138945009789753200

DO - 10.2174/138945009789753200

M3 - Article

VL - 10

SP - 1235

EP - 1244

JO - Current Drug Targets

JF - Current Drug Targets

SN - 1389-4501

IS - 12

ER -